WHO has issued a statement regarding a planned hepatitis B birth dose vaccine trial in Guinea-Bissau. The statement discusses the rationale, objectives, and potential benefits of the trial, while acknowledging the need for further research to address uncertainties around the optimal timing and delivery of the hepatitis B vaccine in this context.
Statement on the planned hepatitis B birth dose vaccine trial in Guinea-Bissau
For informational, non-clinical use. Synthesized analysis of published research — may contain errors. Not medical advice. Consult original sources and your physician.